CelLBxHealth plc (AIM:CLBX)

Market Cap	9.94M -65.7%
Revenue (ttm)	2.62M +29.6%
Net Income	-15.78M
EPS	-0.05
Shares Out	1.14B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,826,601
Average Volume	2,706,228
Open	0.866
Previous Close	0.875
Day's Range	0.866 - 1.200
52-Week Range	0.850 - 11.440
Beta	0.21
RSI	49.56
Earnings Date	Jun 1, 2026

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 119
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CLBX

Financial Performance

In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.